{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:50Z","timestamp":1779322730057,"version":"3.51.4"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To determine the cost effectiveness of molecular monitoring in patients with chronic myeloid leukemia in the chronic phase (CML-CP) compared to no molecular monitoring from a Chinese payer perspective.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Analyses were conducted using a semi-Markov model with a 50-year time horizon. Population data from multicenter registry-based studies of Chinese patients with CML-CP informed the model. Transition probabilities were based on time-to-event data from the literature. Utility values were obtained from published studies and were assumed to be the same for patients with and without molecular monitoring. Costs were based on values commonly used in the Chinese healthcare system, including drug acquisition, drug administration, follow-up, treatment for disease progression, molecular monitoring, and terminal care costs, and were in the local currency (2020 Chinese Yuan RMB [\u00a5]). Outcomes were total life-years (LYs) and quality-adjusted life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Molecular monitoring was dominant to no molecular monitoring, with increased LYs (1.52) and QALYs (1.90) and costs savings (\u00a593,840) over a lifetime compared to no monitoring in discounted analyses. The opportunity of patients that receive molecular monitoring to discontinue treatment during treatment-free remission, an opportunity not afforded to those without molecular monitoring, was the principle driver of this result. Results were similar across multiple clinical scenarios. Particularly, molecular monitoring remained dominant even if the proportion of patients achieving deep molecular response (DMR) was reduced by 10%-30%, or the proportion of patients maintaining DMR for 1 year was reduced by 10%-30% or increased by 10%. Cost savings in these scenarios ranged from \u00a562,230 to \u00a5103,964.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Overall, this analysis demonstrates that adherence to guideline recommendations of regular molecular monitoring of patients with CML-CP treated with TKIs provides significant clinical benefit that leads to substantial cost savings compared to no molecular monitoring from the perspective of a Chinese payer. In a time where healthcare systems have limited resources to allocate to optimal patient care, investment in molecular monitoring is an ideal choice for improving patient benefits at a reduced cost.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0259076","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:28:33Z","timestamp":1635182913000},"page":"e0259076","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China"],"prefix":"10.1371","volume":"16","author":[{"given":"Vikalp Kumar","family":"Maheshwari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Slader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Dani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Gkitzia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengbin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9261-6942","authenticated-orcid":true,"given":"Ricardo","family":"Viana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"issue":"1","key":"pone.0259076.ref001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","article-title":"Chronic myeloid leukemia in Asia","volume":"89","author":"WY Au","year":"2009","journal-title":"Int J Hematol"},{"issue":"6","key":"pone.0259076.ref002","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"E Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"pone.0259076.ref003","first-page":"23","article-title":"Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib","volume":"10","author":"J Emole","year":"2016","journal-title":"Biologics"},{"issue":"1","key":"pone.0259076.ref004","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Z Du","year":"2018","journal-title":"Mol Cancer"},{"issue":"2","key":"pone.0259076.ref005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI118820","article-title":"Griffin, J. D. Hemler, M. E. Bcr\/Abl expression stimulates integrin function in hematopoietic cell lines","volume":"98","author":"N. Bazzoni GC","year":"1996","journal-title":"J Clin Invest"},{"issue":"3","key":"pone.0259076.ref006","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.onc.1201490","article-title":"BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner","volume":"16","author":"N Cambier","year":"1998","journal-title":"Oncogene"},{"issue":"12","key":"pone.0259076.ref007","first-page":"2589","article-title":"The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway","volume":"13","author":"D Cortez","year":"1996","journal-title":"Oncogene"},{"key":"pone.0259076.ref008","article-title":"Treatment of chronic myeloid leukemia in accelerated phase","author":"CA Negrin RS","year":"2020","journal-title":"UpToDate"},{"issue":"1","key":"pone.0259076.ref009","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1186\/s12885-018-4984-3","article-title":"The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study","volume":"18","author":"E Di Felice","year":"2018","journal-title":"BMC Cancer"},{"key":"pone.0259076.ref010","doi-asserted-by":"crossref","first-page":"100257","DOI":"10.1016\/j.eclinm.2020.100257","article-title":"The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP)","volume":"19","author":"CA Umeh","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"5","key":"pone.0259076.ref011","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"K Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"pone.0259076.ref012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3389\/fonc.2020.00883","article-title":"Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia","volume":"10","author":"Annunziata MB","year":"2020","journal-title":"Front Oncol."},{"issue":"4","key":"pone.0259076.ref013","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"A Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"pone.0259076.ref014","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"DM Ross","year":"2013","journal-title":"Blood"},{"issue":"5","key":"pone.0259076.ref015","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"A Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"pone.0259076.ref016","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"J Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"7","key":"pone.0259076.ref017","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"D Rea","year":"2017","journal-title":"Blood"},{"issue":"15","key":"pone.0259076.ref018","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"NvdH Thielen","year":"2013","journal-title":"Eur J Cancer"},{"key":"pone.0259076.ref019","author":"JM Richter","year":"2016","journal-title":"Stopping tyrosine kinase inhibitors in a very large cohort of european chronic myeloid leukemia patients: results of the EURO-SKI trial"},{"key":"pone.0259076.ref020","author":"N Shah","year":"2019","journal-title":"NCCN guidelines updates: discontinuing TKI therapy in the treatment of chronic myeloid leukemia"},{"key":"pone.0259076.ref021","author":"National Comprehensive Cancer Network","year":"2020","journal-title":"NCCN guidelines for patients: chronic myeloid leukemia"},{"key":"pone.0259076.ref022","author":"Leukemia and Lymphocyte Society","year":"2018","journal-title":"Treatment-free remission for chronic myeloid leukemia patients"},{"issue":"suppl_4","key":"pone.0259076.ref023","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdx219","article-title":"Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"A Hochhaus","year":"2017","journal-title":"Ann Oncol."},{"issue":"6","key":"pone.0259076.ref024","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013","journal-title":"Blood"},{"issue":"5","key":"pone.0259076.ref025","first-page":"353","article-title":"The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)","volume":"41","author":"Chinese Society of Hematology CMA","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"pone.0259076.ref026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.japh.2017.01.004","article-title":"Medication adherence, molecular monitoring, and clinical outcomes in patients with chronic myelogenous leukemia in a large HMO","volume":"57","author":"R Haque","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"2","key":"pone.0259076.ref027","first-page":"214","article-title":"Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency","volume":"23","author":"D Latremouille-Viau","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"pone.0259076.ref028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1185\/03007995.2013.812034","article-title":"Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib","volume":"29","author":"SL Goldberg","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"pone.0259076.ref029","article-title":"TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries","author":"A Turkina","year":"2020","journal-title":"Br J Haematol"},{"key":"pone.0259076.ref030","author":"SS Gala","year":"2016","journal-title":"Economic Burden Associated with Chronic Myeloid Leukemia (CML) Treatments in The United States: A Systematic Literature Review"},{"key":"pone.0259076.ref031","author":"ED Sauvage","year":"2016","journal-title":"Modelling The Economic Impact of Implementing Treatment-Free Remission (TFR) In Philadelphia+ (PH+) Chronic Myelogenous Leukemia In Chronic Phase (CML-CP) Patients Treated In First Line (1l) With The Tyrosine Kinase Inhibitors (TKI): Imatinib And Nilotinib"},{"key":"pone.0259076.ref032","author":"VA Shuvaev","year":"2015","journal-title":"Pharmacoeconomical Analysis of Chronic Myelogenous Leukemia Treatment Free Remission"},{"key":"pone.0259076.ref033","first-page":"1","article-title":"Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon","volume":"5","author":"F Elias","year":"2019","journal-title":"J Glob Oncol"},{"issue":"7","key":"pone.0259076.ref034","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/cas.14430","article-title":"Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients","volume":"111","author":"K Yamazaki","year":"2020","journal-title":"Cancer Sci"},{"issue":"4","key":"pone.0259076.ref035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bjh.16245","article-title":"Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia","volume":"187","author":"M Alfayez","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"pone.0259076.ref036","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.29745","article-title":"Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors","volume":"122","author":"K Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"10","key":"pone.0259076.ref037","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications","volume":"112","author":"E Jabbour","year":"2008","journal-title":"Cancer"},{"key":"pone.0259076.ref038","author":"QH J. Jiang","year":"2016","journal-title":"Baseline Characteristics and Early Monitoring of Chinese CML Patients Treated with Dasatinib: Report from a Multicenter, Observational, Registry-Based Study"},{"issue":"7","key":"pone.0259076.ref039","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00277-012-1421-6","article-title":"Cytogenetic profile of 1,863 Ph\/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population","volume":"91","author":"Q Mu","year":"2012","journal-title":"Annals of Hematology"},{"key":"pone.0259076.ref040","year":"2020","journal-title":"Novartis China market access team"},{"issue":"6","key":"pone.0259076.ref041","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/cncr.31187","article-title":"Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase","volume":"124","author":"K Sasaki","year":"2018","journal-title":"Cancer"},{"issue":"5","key":"pone.0259076.ref042","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","article-title":"Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment","volume":"18","author":"M Okada","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"pone.0259076.ref043","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study","volume":"168","author":"FX Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"pone.0259076.ref044","author":"World Health Organization","year":"2020","journal-title":"Chinese Population Life Table"},{"issue":"4","key":"pone.0259076.ref045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/13696998.2016.1271336","article-title":"Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis","volume":"20","author":"G Sheng","year":"2017","journal-title":"Journal of Medical Economics"},{"issue":"29","key":"pone.0259076.ref046","doi-asserted-by":"crossref","first-page":"e7445","DOI":"10.1097\/MD.0000000000007445","article-title":"An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article","volume":"96","author":"B Wu","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"pone.0259076.ref047","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","article-title":"Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"SD Reed","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"pone.0259076.ref048","doi-asserted-by":"crossref","first-page":"A274","DOI":"10.1016\/S1098-3015(11)72013-7","article-title":"Utility values for chronic myeloid leukaemia\u2014chronic phase (CML-CP) health states from the general public in the United Kingdom","volume":"13","author":"J Guest","year":"2010","journal-title":"Value in Health"},{"issue":"21","key":"pone.0259076.ref049","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"C Yamamoto","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"pone.0259076.ref050","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","article-title":"Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia","volume":"14","author":"M Hoyle","year":"2011","journal-title":"Value Health"},{"issue":"42","key":"pone.0259076.ref051","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta16420","article-title":"Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses","volume":"16","author":"T Pavey","year":"2012","journal-title":"Health Technol Assess"},{"issue":"12","key":"pone.0259076.ref052","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial","volume":"109","author":"H Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"20","key":"pone.0259076.ref053","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"H de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"pone.0259076.ref054","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"NP Shah","year":"2014","journal-title":"Blood"},{"issue":"10","key":"pone.0259076.ref055","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"RA Larson","year":"2012","journal-title":"Leukemia"},{"key":"pone.0259076.ref056","author":"Novartis","year":"2017","journal-title":"Compilation of medical service items and prices of medical institutions in Shanghai"},{"key":"pone.0259076.ref057","unstructured":"Beijing medical service price inquiry. [Available from: http:\/\/zyk.bjhd.gov.cn\/sjkf\/wsyl\/201905\/t20190515_4318860.shtml."},{"key":"pone.0259076.ref058","year":"2020","journal-title":"Novartis China market access team"},{"issue":"7","key":"pone.0259076.ref059","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1185\/03007995.2014.904281","article-title":"Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase","volume":"30","author":"A Guerin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"pone.0259076.ref060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/13696998.2016.1271337","article-title":"The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China","volume":"20","author":"G Sheng","year":"2017","journal-title":"J Med Econ"},{"issue":"2","key":"pone.0259076.ref061","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3111\/13696998.2013.862251","article-title":"Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia","volume":"17","author":"A Guerin","year":"2014","journal-title":"J Med Econ"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T17:29:21Z","timestamp":1635182961000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0259076"}},"subtitle":[],"editor":[{"given":"Mohamed A.","family":"Yassin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0259076","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]}}}